CEP-33779
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
Product Specifications
CAS Number
1257704-57-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CEP-33779.html
Purity
99.23
Solubility
DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=CC=C(C2=CC=CN3C2=NC(NC4=CC=CC(N5CCN(C)CC5)=C4)=N3)C=C1)(C)=O
Molecular Formula
C24H26N6O2S
Molecular Weight
462.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Dugan BJ, et al. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779. J Med Chem. 2012 Jun 14;55 (11) :5243-54.|[2]Seavey MM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012 Apr;11 (4) :984-93.|[3]Tang SJ, et al. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochem Pharmacol. 2014 Sep 15;91 (2) :144-56.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2; JAK3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
73100 50 Preparations
EXTRAClean Plasma/Serum Exosome Purification and RNA Isolation Mini Kit
Sign In for Pricing
View Details 
BNC742552-500 1x 500 µL
AKT1 (Prognostic Marker for Neuroendocrine Tumors) (AKT1/2552), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
